secwatch.observer — SEC 8-K summary
======================================

Issuer:     Calidi Biotherapeutics, Inc. (CLDI)
CIK:        0001855485
Form:       8-K
Filed at:   2024-08-14T23:59:59+00:00
Accession:  0001493152-24-031718
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Calidi Biotherapeutics reports Q2 2024 net loss of $5.8M; cash at $1.0M; launches Nova Cell subsidiary
--------------------------------------------------------------------------------

- Net loss of $5.8M ($1.40 per share) vs. $12.5M loss ($14.24 per share) in Q2 2023.
- Cash and restricted cash total ~$1.0M as of June 30, 2024, down from $2.1M at Dec 31, 2023.
- Launched Nova Cell subsidiary with $2M investment from Dr. Ronald Rigor; received additional $1M into Calidi.
- Appointed Dr. George Peoples to Board of Directors and Dr. Mark Gilbert to Medical Advisory Board.
- Received new U.S. patent for SuperNova technology; raised $2.5M from warrant exercises in July/August 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1855485/000149315224031718/0001493152-24-031718-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1855485/000149315224031718/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-031718

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer